JP2009532044A5 - - Google Patents

Info

Publication number
JP2009532044A5
JP2009532044A5 JP2009503410A JP2009503410A JP2009532044A5 JP 2009532044 A5 JP2009532044 A5 JP 2009532044A5 JP 2009503410 A JP2009503410 A JP 2009503410A JP 2009503410 A JP2009503410 A JP 2009503410A JP 2009532044 A5 JP2009532044 A5 JP 2009532044A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
units
lna
oligonucleotide according
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009503410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532044A (ja
JP5198430B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2007/000168 external-priority patent/WO2007112753A2/en
Publication of JP2009532044A publication Critical patent/JP2009532044A/ja
Publication of JP2009532044A5 publication Critical patent/JP2009532044A5/ja
Application granted granted Critical
Publication of JP5198430B2 publication Critical patent/JP5198430B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009503410A 2006-04-03 2007-03-30 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物 Expired - Fee Related JP5198430B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US78899506P 2006-04-03 2006-04-03
DKPA200600478 2006-04-03
US60/788,995 2006-04-03
DKPA200600478 2006-04-03
US79681306P 2006-05-01 2006-05-01
US60/796,813 2006-05-01
DKPA200600615 2006-05-01
DKPA200600615 2006-05-01
US83871006P 2006-08-18 2006-08-18
US60/838,710 2006-08-18
DKPA200601401 2006-10-30
DKPA200601401 2006-10-30
PCT/DK2007/000168 WO2007112753A2 (en) 2006-04-03 2007-03-30 Pharmaceutical composition comprising anti-mirna antisense oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012242996A Division JP2013078317A (ja) 2006-04-03 2012-11-02 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2009532044A JP2009532044A (ja) 2009-09-10
JP2009532044A5 true JP2009532044A5 (enExample) 2010-06-03
JP5198430B2 JP5198430B2 (ja) 2013-05-15

Family

ID=38564007

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009503410A Expired - Fee Related JP5198430B2 (ja) 2006-04-03 2007-03-30 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2009503411A Expired - Fee Related JP5814505B2 (ja) 2006-04-03 2007-03-30 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2012242996A Pending JP2013078317A (ja) 2006-04-03 2012-11-02 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2014022650A Expired - Fee Related JP5872603B2 (ja) 2006-04-03 2014-02-07 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2015221396A Expired - Fee Related JP6326025B2 (ja) 2006-04-03 2015-11-11 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2009503411A Expired - Fee Related JP5814505B2 (ja) 2006-04-03 2007-03-30 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2012242996A Pending JP2013078317A (ja) 2006-04-03 2012-11-02 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2014022650A Expired - Fee Related JP5872603B2 (ja) 2006-04-03 2014-02-07 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
JP2015221396A Expired - Fee Related JP6326025B2 (ja) 2006-04-03 2015-11-11 ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物

Country Status (12)

Country Link
US (8) US20100004320A1 (enExample)
EP (3) EP2194129A3 (enExample)
JP (5) JP5198430B2 (enExample)
KR (1) KR101407707B1 (enExample)
AU (1) AU2007234191B2 (enExample)
CA (4) CA2648132C (enExample)
DK (1) DK2666859T3 (enExample)
EA (1) EA015570B1 (enExample)
ES (1) ES2715625T3 (enExample)
IL (1) IL194007A0 (enExample)
MX (1) MX2008012219A (enExample)
WO (2) WO2007112754A2 (enExample)

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
PL1747023T5 (pl) 2004-05-04 2017-05-31 Univ Leland Stanford Junior Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
US8592384B2 (en) 2005-04-04 2013-11-26 The Board Of Regents Of The University Of Texas System Micro-RNA's that regulate muscle cells
CN101341259B (zh) 2005-08-01 2011-12-21 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP5523705B2 (ja) 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Ｍｉｒ−１２２ａをモジュレートする使用方法
EP1937280B1 (en) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Compositions for the therapy of bcl2-associated cancers
ES2429404T3 (es) 2006-01-05 2013-11-14 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico y el pronóstico del cáncer de pulmón
EP2487261B1 (en) 2006-01-05 2015-07-01 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
CA2646051A1 (en) 2006-03-20 2007-09-27 Carlo M. Croce Microrna fingerprints during human megakaryocytopoiesis
PL2666859T3 (pl) * 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
ES2715625T3 (es) * 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
CA3044969A1 (en) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
WO2008008430A2 (en) 2006-07-13 2008-01-17 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
ES2397439T3 (es) 2006-08-01 2013-03-07 Board Of Regents Of The University Of Texas System Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina
US8188255B2 (en) 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
AU2007323469B2 (en) 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
CN103555825B (zh) 2007-01-31 2015-09-30 俄亥俄州立大学研究基金会 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
EP2126079A1 (en) 2007-03-22 2009-12-02 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8288358B2 (en) 2007-03-26 2012-10-16 Newcastle Innovation Ltd. Therapeutic targets and molecules
WO2008136971A1 (en) * 2007-04-30 2008-11-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
US8691965B2 (en) 2007-06-14 2014-04-08 Mirx Therapeutics Aps Oligonucleotides for modulating target RNA activity
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
CA2695184A1 (en) 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
US8481507B2 (en) 2007-07-31 2013-07-09 The Board Of Regents, The University Of Texas System Micro-RNAs that control myosin expression and myofiber identity
US8440636B2 (en) 2007-07-31 2013-05-14 The Board Of Regents, The University Of Texas System Micro-RNA family that modulates fibrosis and uses thereof
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
AU2013273821B2 (en) * 2007-10-04 2016-03-10 Roche Innovation Center Copenhagen A/S Micromirs
CA2702241A1 (en) * 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas
JP2011504093A (ja) 2007-10-26 2011-02-03 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 脆弱性ヒスチジン三連構造（ｆｈｉｔ）相互作用を同定するための方法およびその使用
CN101980712B (zh) * 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
JP5654352B2 (ja) * 2007-11-09 2015-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節
GB0802754D0 (en) * 2008-02-14 2008-03-26 Inst Superiore Di Sanito Antisense RNA targetting CXCR4
WO2009105759A2 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP3064584A3 (en) * 2008-02-28 2016-12-07 The Ohio State University Research Foundation Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2265291B1 (en) 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
EP2281903B1 (en) 2008-04-30 2017-01-04 NEC Corporation METHOD FOR EVALUATION OF CANCER BY USING miRNA CANCER MARKER
CN102149827B (zh) 2008-06-11 2014-08-20 由卫生与公众服务部代表的美利坚合众国政府 MiR-26家族作为肝细胞癌和对治疗的应答性的预测性标志物的用途
AU2009270005B2 (en) * 2008-06-16 2014-07-24 Academisch Ziekenhuis Maastricht Means and methods for counteracting, delaying and/or preventing heart disease
EP2297357B1 (en) 2008-06-27 2012-10-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Prediction of antiviral therapy response
WO2010012667A1 (en) * 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
EP2191834A1 (en) * 2008-11-26 2010-06-02 Centre National De La Recherche Scientifique (Cnrs) Compositions and methods for treating retrovirus infections
KR101829469B1 (ko) * 2008-12-04 2018-03-30 큐알엔에이, 인크. Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
US9132147B2 (en) 2008-12-31 2015-09-15 Roche Innovation Center Copenhagen Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
MX2011008190A (es) 2009-02-04 2011-10-06 Univ Texas Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
AU2010234806B2 (en) 2009-03-31 2014-05-22 The United States Of America As Represented By The Secretary Department Of Health And Human Services Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
AU2010250838B2 (en) 2009-05-20 2016-01-21 Eth Zurich Targeting microRNAs for metabolic disorders
WO2010135714A2 (en) * 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
US20110190372A1 (en) * 2009-08-07 2011-08-04 New York University Compositions and methods for treating inflammatory disorders
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
CN102002493B (zh) * 2009-09-01 2013-04-10 中国科学院上海生命科学研究院 小rna-326制备药物的应用
WO2011032100A1 (en) * 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
JP5960060B2 (ja) 2009-11-23 2016-08-02 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
US20120302626A1 (en) 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
EP2536436A4 (en) * 2010-01-20 2015-01-14 Univ Texas ANTIMIR-451 FOR THE TREATMENT OF POLYCYCLES
WO2011111715A1 (ja) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
ES2743600T3 (es) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Métodos de tratamiento de los trastornos inflamatorios vasculares
WO2011117353A1 (en) * 2010-03-24 2011-09-29 Mirrx Therapeutics A/S Bivalent antisense oligonucleotides
CN102884206B (zh) * 2010-04-21 2014-07-30 阿姆斯特丹大学学术医学中心 用于确定心血管疾病的风险的手段和方法
EP2563935B1 (en) 2010-04-30 2014-04-16 Exiqon A/S In situ hybridization method and buffer.
US20110281933A1 (en) * 2010-05-13 2011-11-17 Saint Louis University Methods and compositions for the management of cardiovascular disease with oligonucleotides
US20130210883A1 (en) 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors
FR2960130B1 (fr) 2010-05-21 2013-11-01 Dominique Cingotti Agent edulcorant contenant un extrait de stevia rebaudiana bertoni
CN103210085B (zh) * 2010-05-21 2018-09-25 农业科学维也纳大学 用于治疗或诊断骨障碍和/或心血管障碍的组合物
AU2011261213B2 (en) * 2010-06-04 2015-05-21 Board Of Regents, The University Of Texas System Regulation of metabolism by miR-378
EP2580328A2 (en) 2010-06-11 2013-04-17 Cellartis AB Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
CN103097535A (zh) 2010-07-12 2013-05-08 国立大学法人鸟取大学 利用miRNA导入的新型hiPSC制作法
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
WO2012027601A2 (en) 2010-08-25 2012-03-01 The General Hospital Corporation Methods targeting mir-33 micrornas for regulating lipid metabolism
US20130150431A1 (en) 2010-08-27 2013-06-13 New York University Mir-33 inhibitors and uses thereof
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
CN102031261B (zh) * 2010-10-27 2015-04-22 南京医科大学 一种与妊娠期糖尿病相关的血清/血浆miRNA标志物及其应用
US9248144B2 (en) 2010-11-11 2016-02-02 University Of Miami Compositions, kits and methods for treatment of cardiovascular, immunological and inflammatory diseases
EP2638912A4 (en) 2010-11-12 2015-01-21 Nat Univ Corp Ehime Univ COMPOSITIONS WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST MICRO RNA
CA2816603A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2640368B1 (en) 2010-11-15 2020-12-30 The Ohio State University Research Foundation Controlled release mucoadhesive systems
CN102041316A (zh) * 2010-11-30 2011-05-04 华东师范大学 miRNA-219化合物作为脑胶质瘤标志物的应用
CN103380215A (zh) 2010-12-15 2013-10-30 米拉根医疗公司 包含锁定核苷酸的微rna抑制剂
SG191174A1 (en) 2010-12-20 2013-07-31 Agency Science Tech & Res Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
CN102174516A (zh) * 2011-01-20 2011-09-07 中南大学 一种与ebv感染相关的鼻咽癌诊断和治疗的分子靶标及其应用
EP2683387A4 (en) 2011-03-07 2014-09-03 Univ Ohio State MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
WO2012142313A2 (en) * 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
WO2012145374A1 (en) 2011-04-19 2012-10-26 Regulus Therapeutics Inc. TARGETING miR-378 FAMILY MEMBERS FOR THE TREATMENT OF METABOLIC DISORDERS
SG194636A1 (en) 2011-04-25 2013-12-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
WO2012149557A1 (en) 2011-04-28 2012-11-01 New York University miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION
WO2012175733A1 (en) 2011-06-23 2012-12-27 Santaris Pharma A/S Hcv combination therapy
US20140194491A1 (en) * 2011-06-24 2014-07-10 Syddansk Universitet Modulation of microrna-138 for the treatment of bone loss
KR20140064765A (ko) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv 조합 치료
US20140213632A1 (en) 2011-06-30 2014-07-31 Stella Aps HCV Combination Therapy
CN102908621A (zh) * 2011-08-02 2013-02-06 中国科学院上海生命科学研究院 miRNAs作为调节胰岛素敏感性的靶标的新用途
EP2751271A1 (en) 2011-08-31 2014-07-09 Universität Zürich Prorektorat MNW Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis
CN102978278B (zh) * 2011-09-07 2016-09-28 中国科学院动物研究所 内源性的非编码小RNAs及其应用
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
JP6177243B2 (ja) 2011-10-06 2017-08-09 ミラゲン セラピューティクス， インコーポレイテッド マイクロｒｎａの調節による全身エネルギーホメオスタシスの制御
US10184151B2 (en) * 2011-10-11 2019-01-22 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
GB201117482D0 (en) * 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
JP2014533099A (ja) 2011-11-07 2014-12-11 ステラ・アンパルトセルスカブＳｔｅｌｌａ Ａｐｓ Ｈｃｖ＋患者におけるミクロｒｎａ−１２２阻害剤の有効性をチェックするための予測方法
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
EP2790735A4 (en) * 2011-12-13 2015-12-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS RELATING TO MIR-21 AND MIR-29A, EXOSOME INHIBITION, AND CANCER METASTASIS
EP2791337A1 (en) * 2011-12-15 2014-10-22 Oncostamen S.r.l. Micrornas and uses therof
US9447471B2 (en) * 2011-12-29 2016-09-20 Quest Diagnostics Investments Incorporated Microrna profiling for diagnosis of dysplastic nevi and melanoma
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
EA030211B1 (ru) 2012-04-25 2018-07-31 Регьюлэс Терапьютикс Инк. Соединения на основе микрорнк и способы модулирования активности mir-21
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
BR112014028634A2 (pt) 2012-05-16 2017-06-27 Rana Therapeutics Inc composições e métodos para modulação da expressão de utrn
EP3511416A1 (en) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Compositions and methods for modulating gene expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
CA2873769A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating hemoglobin gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
BR112014028644A2 (pt) 2012-05-16 2017-08-15 Rana Therapeutics Inc Composições e métodos para modulação da expressão de atp2a2
US10316367B2 (en) 2012-06-21 2019-06-11 Ruprecht-Karls-Universität Heidelberg Circulating miRNAs as markers for breast cancer
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
DK3354734T3 (da) 2012-06-21 2020-06-29 Miragen Therapeutics Inc Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster
EP2885008B1 (en) 2012-08-15 2018-11-07 University Of Virginia Patent Foundation Compositions and methods for treating peripheral arterial disease
KR101667169B1 (ko) * 2012-08-20 2016-10-17 국립연구개발법인 고쿠리츠간켄큐센터 암 치료제
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN114306315A (zh) * 2012-10-31 2022-04-12 洛克菲勒大学 结肠癌的治疗和诊断
JP6452614B2 (ja) 2012-11-15 2019-01-16 ロシュ イノベーション センター コペンハーゲン エーエス オリゴヌクレオチドコンジュゲート
DK2925866T3 (en) * 2012-11-30 2018-10-29 Univ Aarhus CIRCULAR RNA FOR INHIBITING MICRO-RNA
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
DK2951305T3 (en) 2013-01-30 2018-10-29 Hoffmann La Roche LNA oligonucleotide KULHYDRATKONJUGATER
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
WO2014151835A1 (en) * 2013-03-15 2014-09-25 Miragen Therapeutics, Inc Locked nucleic acid inhibitor of mir-145 and uses thereof
AU2014233115B2 (en) * 2013-03-15 2019-08-01 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
JP6649248B2 (ja) 2013-05-01 2020-02-19 レグルス セラピューティクス インコーポレイテッド 細胞取り込みの向上のための化合物および方法
CN103293318B (zh) * 2013-05-22 2014-10-29 吉林大学 利用地高辛标记EDC交联桥连法检测miRNAs方法
US10053690B2 (en) 2013-06-12 2018-08-21 New York University Anti-miR-27b and anti-miR-148a oligonucleotides as therapeutic tools for treating dyslipidemias and cardiovascular diseases
US9976140B2 (en) 2013-06-14 2018-05-22 Joslin Diabetes Center, Inc. Microrna and uses in brown fat differentiation
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9
EP3024933A4 (en) * 2013-07-24 2017-03-15 The General Hospital Corporation Agents and methods for inhibiting mir-148a for the modulation of cholesterol levels
WO2015020122A1 (ja) * 2013-08-08 2015-02-12 国立大学法人 大阪大学 尿路上皮癌の診断または治療剤
US9994846B2 (en) 2013-10-25 2018-06-12 Regulus Therapeutics Inc. MicroRNA compounds and methods for modulating miR-21 activity
US9458458B2 (en) * 2013-11-11 2016-10-04 Emory University Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
US20160362688A1 (en) * 2014-02-12 2016-12-15 Thomas Jefferson University Compositions and methods of using microrna inhibitors
WO2015175539A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
EP3177722A4 (en) 2014-07-31 2018-01-17 Agency For Science, Technology And Research Modified antimir-138 oligonucleotides
BR112017001931A2 (pt) 2014-08-07 2017-11-28 Regulus Therapeutics Inc direcionamento de micrornas para distúrbios metabólicos
EP3230453B1 (en) 2014-09-21 2020-05-20 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Downregulating mir-132 for the treatment of lipid related disorders
CN104306988B (zh) * 2014-09-25 2017-02-15 中国医学科学院基础医学研究所 miR‑431在制备治疗肌肉疾病的药物中的用途
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016077347A1 (en) 2014-11-10 2016-05-19 The Regents Of The University Of California Mir-214 as a diagnostic and prognostic biomarker specific for ulcerative colitis and a mir-214 inhibitor for treatment of same
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
EP3020813A1 (en) 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
EP3256591A4 (en) 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
EP3271460A4 (en) 2015-03-17 2019-03-13 The General Hospital Corporation RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
WO2016164463A1 (en) 2015-04-07 2016-10-13 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
EP3303590A4 (en) * 2015-06-05 2019-01-02 Miragen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
CN107922947A (zh) * 2015-06-05 2018-04-17 米拉根医疗股份有限公司 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
EP3331546B1 (en) 2015-08-03 2023-10-04 Biokine Therapeutics Ltd. Cxcr4 inhibitor for the treatment of cancer
DK3341479T3 (da) 2015-08-24 2020-02-24 Roche Innovation Ct Copenhagen As LNA-G-Proces
JP2018528967A (ja) * 2015-09-22 2018-10-04 ミラゲン セラピューティクス， インコーポレイテッド Ｍｉｒ−１９調節物質およびその使用
EP3355932B1 (en) 2015-10-02 2023-04-12 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugation process
US10870852B2 (en) * 2015-10-06 2020-12-22 University Of Virginia Patent Foundation Compositions and methods for treating diabetic retinopathy
JP6666002B2 (ja) 2015-10-07 2020-03-13 国立大学法人京都大学 Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017067970A1 (en) 2015-10-22 2017-04-27 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
JOP20200228A1 (ar) 2015-12-21 2017-06-16 Novartis Ag تركيبات وطرق لخفض تعبير البروتين tau
CN107012199A (zh) * 2016-01-28 2017-08-04 上海市东方医院 一种在血浆和血清中检测miRNA的方法
WO2017147087A1 (en) 2016-02-25 2017-08-31 The Brigham And Women's Hospital, Inc. Treatment methods for fibrosis targeting smoc2
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US11267843B2 (en) 2016-03-18 2022-03-08 Roche Innovation Center Copenhagen A/S Stereodefining L-monomers
CN109311925B (zh) 2016-05-12 2022-06-03 罗氏创新中心哥本哈根有限公司 立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
US11015196B2 (en) 2016-05-20 2021-05-25 The General Hospital Corporation Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
WO2017216340A1 (en) 2016-06-17 2017-12-21 F. Hoffmann-La Roche Ag In vitro nephrotoxicity screening assay
US11479818B2 (en) 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
US11253601B2 (en) 2016-07-11 2022-02-22 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
JP2019521176A (ja) 2016-07-18 2019-07-25 ジャーン バイオセラピューティクス エルエルシーＪａａｎ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 心疾患の処置のための組成物及び方法
EP3494219A1 (en) 2016-08-03 2019-06-12 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
ES2659845B1 (es) * 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
WO2018080658A1 (en) * 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
WO2018081817A2 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN110753758A (zh) 2016-12-22 2020-02-04 俄亥俄州国家创新基金会 用于将体细胞重编程为诱导的血管生成细胞的组合物和方法
US11591362B2 (en) 2017-03-29 2023-02-28 Roche Innovation Center Copenhagen A/S Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
US11542294B2 (en) 2017-03-29 2023-01-03 Roche Innovation Center Copenhagen A/S Rapid unylinker cleavage
US11484570B2 (en) 2017-04-14 2022-11-01 University Of Massachusetts Targeting cell tropism receptors to inhibit cytomegalovirus infection
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
EP3645544B1 (en) 2017-06-28 2023-05-10 Roche Innovation Center Copenhagen A/S Multiple coupling&oxidation method
EP3694995A1 (en) 2017-10-13 2020-08-19 Roche Innovation Center Copenhagen A/S Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
ES3040707T3 (en) 2017-11-01 2025-11-04 Dana Farber Cancer Inst Inc Usp1 or uaf1 inhibitors for use in treating cancer
CN108272815B (zh) * 2017-12-06 2020-09-11 南方医科大学深圳医院 EB病毒miR-BART10-5p抑制剂的应用
CN108220381A (zh) * 2017-12-07 2018-06-29 国家卫生计生委科学技术研究所 试剂在制备药物中的用途以及筛选药物的方法
KR20200104347A (ko) 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드
US20200339982A1 (en) 2017-12-22 2020-10-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
KR20200104302A (ko) 2017-12-22 2020-09-03 로슈 이노베이션 센터 코펜하겐 에이/에스 신규 티오포스포르아미다이트
US12178855B2 (en) 2018-01-10 2024-12-31 Translate Bio Ma, Inc. Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
WO2019178410A1 (en) * 2018-03-14 2019-09-19 Beth Israel Deaconess Medical Center Micro-rna and obesity
CN108220427B (zh) * 2018-03-20 2021-09-28 南京大学 一种用于鉴别诊断BHD综合征与原发性自发性气胸的血浆microRNA标记物及应用
JP7279081B2 (ja) 2018-05-08 2023-05-22 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１２２を調節するためのマイクロｒｎａ化合物及び方法
EP3790893A4 (en) 2018-05-11 2022-03-16 University Of Massachusetts METHOD OF IMPROVING LEPTIN SENSITIVITY FOR TREATMENT OF OBESITY AND DIABETES
EP3793685A1 (en) * 2018-05-18 2021-03-24 F. Hoffmann-La Roche AG Pharmaceutical compositions for treatment of microrna related diseases
WO2019232132A1 (en) * 2018-05-30 2019-12-05 The Regents Of The University Of California Methods of enhancing immunity
CN110777199B (zh) * 2018-07-24 2023-11-14 长庚医疗财团法人高雄长庚纪念医院 干癣性关节炎的诊断及治疗及其相应的试剂盒
AU2019313527A1 (en) 2018-07-31 2021-02-11 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
MX2020013270A (es) 2018-07-31 2021-02-18 Roche Innovation Ct Copenhagen As Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
AU2019316103B2 (en) 2018-08-02 2026-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP7499754B2 (ja) 2018-08-23 2024-06-14 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブ Ｍｉｃｒｏｒｎａ－１３４バイオマーカー
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia
EP3620519A1 (en) 2018-09-04 2020-03-11 F. Hoffmann-La Roche AG Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
CN110468202A (zh) * 2019-01-18 2019-11-19 宁夏医科大学 一种靶向TIGIT的miR-206作为肝癌诊断和治疗新型分子的用途
WO2020152303A1 (en) 2019-01-25 2020-07-30 F. Hoffmann-La Roche Ag Lipid vesicle for oral drug delivery
BR112021016354A2 (pt) 2019-02-20 2021-10-19 Roche Innovation Center Copenhagen A/S Composto, processo para a fabricação de um composto de fórmula, uso de um composto e invenção
CN113490742A (zh) 2019-02-20 2021-10-08 罗氏创新中心哥本哈根有限公司 膦酰基乙酸酯缺口聚物寡核苷酸
CN118512468A (zh) * 2019-02-26 2024-08-20 首尔大学校产学协力团 包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
EP3931348B1 (en) 2019-02-26 2023-08-09 Roche Innovation Center Copenhagen A/S Oligonucleotide formulation method
US11466274B2 (en) 2019-05-31 2022-10-11 Aligos Therapeutics, Inc. Modified gapmer oligonucleotides and methods of use
US20220257790A1 (en) 2019-06-26 2022-08-18 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof
CN110548041A (zh) * 2019-08-30 2019-12-10 中国医科大学附属盛京医院 LNA-anti-miR-150在制备预防或治疗肾脏纤维化药物中的用途
CN111057790B (zh) * 2019-12-11 2022-08-30 石河子大学 miRNA在制备用于检测KSHV潜伏感染的试剂盒中的用途
EP4464779A3 (en) * 2020-02-14 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
CN115176010A (zh) 2020-02-28 2022-10-11 豪夫迈·罗氏有限公司 用于调节cd73外显子7剪接的寡核苷酸
JP7773730B2 (ja) * 2020-03-02 2025-11-20 国立大学法人京都大学 ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療
KR102691806B1 (ko) * 2020-04-23 2024-08-06 주식회사 바이오오케스트라 상향조절된 mirna의 진단 및 치료를 위한 용도
KR102555878B1 (ko) * 2020-04-23 2023-07-17 주식회사 바이오오케스트라 하향조절된 mirna의 진단 및 치료를 위한 용도
WO2021240533A1 (en) * 2020-05-29 2021-12-02 National Institute Of Immunology Dna damage dependent microrna signature for cancers, methods and uses related thereto
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
CN112301130B (zh) * 2020-11-12 2021-11-30 苏州京脉生物科技有限公司 一种肺癌早期检测的标志物、试剂盒及方法
AU2022219031A1 (en) 2021-02-12 2023-09-07 Merand Pharmaceuticals, Inc. Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
AU2022242781A1 (en) * 2021-03-26 2023-10-26 Neumirna Therapeutics Aps Microrna-27b inhibitors
US20240240188A1 (en) 2021-06-04 2024-07-18 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
WO2022260162A1 (ja) * 2021-06-11 2022-12-15 国立大学法人京都大学 Ｎａｓｈの予防及び／又は治療剤
EP4105328A1 (en) 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
KR102329524B1 (ko) * 2021-08-06 2021-11-23 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
WO2023013818A1 (ko) * 2021-08-06 2023-02-09 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
JP2024531342A (ja) 2021-08-19 2024-08-29 ニューミルナ セラピューティクス エーピーエス アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
MX2024003529A (es) 2021-10-08 2024-04-01 Regulus Therapeutics Inc Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica.
AU2022360530A1 (en) * 2021-10-08 2024-03-28 Regulus Therapeutics Inc. Methods and compositions for avoiding off-target effects
KR102711428B1 (ko) * 2022-04-28 2024-09-26 차의과학대학교 산학협력단 삼중음성유방암의 예방, 개선 또는 치료용 약학 조성물
AU2023314808A1 (en) 2022-07-29 2025-03-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
EP4612184A1 (en) 2022-11-04 2025-09-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
EP4622651A1 (en) * 2022-11-22 2025-10-01 The Regents of the University of California Inhibitory nucleic acids and methods of use thereof
JP2026503704A (ja) 2023-01-27 2026-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 修飾されたラブドウイルス糖タンパク質およびその使用
CN118006611B (zh) * 2024-02-23 2025-03-18 广东省科学院动物研究所 一种杀白蚁的miRNA及其联合绿僵菌防治白蚁的方法
TW202543654A (zh) * 2024-02-27 2025-11-16 丹麥商諾佛 儂迪克股份有限公司 心臟及纖維化病症之預防及治療

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US4920115A (en) 1988-12-28 1990-04-24 Virginia Commonwealth University Method of lowering LDL cholesterol in blood
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
JPH06311885A (ja) 1992-08-25 1994-11-08 Mitsubishi Kasei Corp Ｃ型肝炎ウイルス遺伝子に相補的なアンチセンス化合物
DK0662157T3 (da) 1992-09-10 2001-08-27 Isis Pharmaceuticals Inc Præparater og fremgangsmåde til behandling af Hepatitis C-virus-associerede sygdomme
US6423489B1 (en) * 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6433159B1 (en) * 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
JPH10503364A (ja) 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
MX9709914A (es) 1995-06-07 1998-03-31 Pfizer Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
YU23499A (sh) 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a
AU726374B2 (en) * 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
HK1048639A1 (zh) 1999-03-18 2003-04-11 埃克西库恩公司 木-lna类似物
AU3418800A (en) 1999-03-24 2000-10-09 Exiqon A/S Improved synthesis of (2.2.1)bicyclo nucleosides
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU776362B2 (en) 1999-05-04 2004-09-09 Roche Innovation Center Copenhagen A/S L-ribo-LNA analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
JP2003511016A (ja) 1999-10-04 2003-03-25 エクシコン エ／エス オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計
IL139450A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
ATE325806T1 (de) 2000-10-04 2006-06-15 Santaris Pharma As Verbesserte synthese von purin-blockierten nukleinsäure-analoga
AU2002322478A1 (en) 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2002094250A2 (en) 2001-05-18 2002-11-28 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
DE60202681T2 (de) 2001-07-12 2006-01-12 Santaris Pharma A/S Verfahren zur herstellung des lna phosphoramidite
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
CA2459347C (en) * 2001-09-04 2012-10-09 Exiqon A/S Locked nucleic acid (lna) compositions and uses thereof
JP4371812B2 (ja) 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ マイクロｒｎａ分子
ATE519774T1 (de) 2002-02-20 2011-08-15 Sirna Therapeutics Inc Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
ES2290448T3 (es) 2002-05-08 2008-02-16 Santaris Pharma A/S Sistesis de derivados de acidos nucleicos bloqueados.
AU2003264038A1 (en) * 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
UA79300C2 (en) 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
JP4986109B2 (ja) 2002-11-13 2012-07-25 ジェンザイム・コーポレーション アポリポタンパク質ｂ発現のアンチセンス調節
EP2752488B1 (en) * 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Antisense design
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
FR2848572B1 (fr) * 2002-12-12 2005-12-09 Univ Joseph Fourier Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
US20060247193A1 (en) 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
DE602004022020D1 (de) 2003-02-10 2009-08-27 Santaris Pharma As Oligomere verbindungen zur modulation der expression von survivin
AU2004209599A1 (en) * 2003-02-10 2004-08-19 Santaris Pharma A/S Oligomeric compounds for the modulation of ras expression
EP2141234B1 (en) * 2003-03-21 2016-04-27 Roche Innovation Center Copenhagen A/S Short Interfering RNA (siRNA) Analogues
EP2669377A3 (en) * 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CA2532795A1 (en) 2003-08-07 2005-02-17 Avi Biopharma, Inc. Sense antiviral compound and method for treating ssrna viral infection
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
JP5654722B2 (ja) 2003-11-26 2015-01-14 ユニバーシティ オブ マサチューセッツ 短鎖ｒｎａ機能の配列特異的阻害法
UA83510C2 (en) 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
NZ548254A (en) * 2003-12-23 2008-09-26 Santaris Pharma As Oligomeric compounds for the modulation of BCL-2
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
EP1735459B1 (en) 2004-04-07 2012-01-25 Exiqon A/S Methods for quantification of micrornas and small interfering rnas
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP1745150A4 (en) * 2004-04-20 2008-02-27 Genaco Biomedial Products Inc METHOD FOR DETECTING NCRNA
PL1747023T5 (pl) 2004-05-04 2017-05-31 Univ Leland Stanford Junior Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
WO2006093526A2 (en) 2004-07-21 2006-09-08 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
FR2873694B1 (fr) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
PT2409713E (pt) 2004-08-10 2015-10-09 Genzyme Corp Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
WO2006027776A1 (en) 2004-09-07 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
CN101133074B (zh) 2004-09-24 2012-05-30 阿尔尼拉姆医药品有限公司 APOB的RNAi调节及其用途
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20060134189A1 (en) 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
NZ563009A (en) 2005-04-19 2011-05-27 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
US20060265771A1 (en) * 2005-05-17 2006-11-23 Lewis David L Monitoring microrna expression and function
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090203893A1 (en) 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
JP5523705B2 (ja) 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Ｍｉｒ−１２２ａをモジュレートする使用方法
AU2006291836B2 (en) 2005-09-15 2012-02-23 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-Bl00 expression
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
JP5213723B2 (ja) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ， インコーポレーテッド マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物
ES2715625T3 (es) 2006-04-03 2019-06-05 Roche Innovation Ct Copenhagen As Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN
CA3044969A1 (en) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
US20080199961A1 (en) 2006-08-25 2008-08-21 Avi Biopharma, Inc. ANTISENSE COMPOSITION AND METHOD FOR INHIBITION OF miRNA BIOGENESIS
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
AU2007296055A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US7803784B2 (en) 2006-10-24 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Modulation of T cell signaling threshold and T cell sensitivity to antigens
AU2007323469B2 (en) 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
WO2008074328A2 (en) 2006-12-21 2008-06-26 Exiqon A/S Microrna target site blocking oligos and uses thereof
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
WO2008124384A2 (en) 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
US20090082297A1 (en) 2007-06-25 2009-03-26 Lioy Daniel T Compositions and Methods for Regulating Gene Expression
WO2009032083A1 (en) 2007-08-29 2009-03-12 President And Fellows Of Harvard College Methods of increasing gene expression through rna protection
DK2205737T3 (da) 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010000665A1 (en) 2008-06-30 2010-01-07 Santaris Pharma A/S Antidote oligomers
US8398734B2 (en) 2008-08-01 2013-03-19 Twister B.V. Cyclonic separator with a volute outlet duct
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides

Similar Documents

Publication Publication Date Title
JP2009532044A5 (enExample)
JP2009532392A5 (enExample)
JP7798836B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
IL300119A (en) Oligonucleotides to induce paternal UBE3A expression
JP2011504362A5 (enExample)
JP2019513771A (ja) トリチル−モノ−ＧａｌＮＡｃ化合物とその利用
JP7515400B2 (ja) Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用
JP2010505432A5 (enExample)
Liczner et al. Beyond ribose and phosphate: selected nucleic acid modifications for structure–function investigations and therapeutic applications
JP2021505129A5 (enExample)
JP2021524277A (ja) Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
JP2020521491A5 (enExample)
JP7813254B2 (ja) Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド
WO2023078883A1 (en) Oligonucleotides for modulating apolipoprotein e4 expression
JP2023506547A (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2022521510A (ja) ホスホノアセテートギャップマー型オリゴヌクレオチド
JP2021510295A (ja) Ｇｓｋ３ｂ発現を調節するためのオリゴヌクレオチド
BR112020012427A2 (pt) oligonucleotídeo, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, processo para a fabricação de um oligonucleotídeo, oligonucleotídeo fabricado e invenção
JP2024546993A (ja) Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
JPWO2023098908A5 (enExample)
WO2023159138A2 (en) Use of dinucleotide repeat rnas to treat cancer
NZ770352A (en) Oligonucleotides for modulating tau expression
NZ770352B2 (en) Oligonucleotides for modulating tau expression
CN113474352A (zh) 新型亚磷酰胺
HK40060207A (en) Novel phosphoramidites